This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

Regulatory reviews rocked health stocks, such as Wyeth (WYE), in both directions, while earnings gave others a nudge on Tuesday.

The Food and Drug Administration asked for more information on Wyeth's prospective menopause-symptoms treatment Pristiq -- specifically, the drug's potential risks of liver and cardiovascular side effects, according to the company. It pushed the stock down $4.36, or 7.8%, to $51.64.

On the other hand, the FDA granted Neurochem's (NRMX) investigational Alzheimer's treatment candidate tramiprosate Fast Track status, which expedites the review of drugs that treat serious or life-threatening conditions and that address an unmet medical need for a condition.

Neurochem is meeting with the FDA in August to discuss tramiprosate's phase III program. The company's stock climbed 34 cents, or 5.8%, to $6.22.

Also, the FDA's Oncologic Drugs Advisory Committee voted to recommend approval for Eli Lilly's (LLY - Get Report) osteoporosis drug evista for a new use to reduce invasive breast cancer risk in postmenopausal women with osteoporosis and postmenopausal women at a high risk for breast cancer. The recommendation, however, is nonbinding. The company reported better-than-expected earnings on Tuesday, and upped its guidance for the year.

Eli Lilly rose $1.46, or 2.5%, to $58.58. It's a component of the Amex Biopharmaceutical index, which was down 3.76, or 1.1%, to 350.10.

Orexigen Therapeutics (OREX - Get Report) said Tuesday that a phase IIb trial for obesity drug candidate Empatic met its primary endpoint. The company said the trial demonstrated statistically significant weight loss against the placebo and was safe and well tolerated. Shares of Orexigen initially climbed but were recently down 0.5% at $14.15.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIB $40.21 1.40%
DGX $75.58 0.79%
EW $104.36 0.54%
LLY $75.39 0.69%
OREX $0.41 -5.30%


Chart of I:DJI
DOW 17,711.90 +60.64 0.34%
S&P 500 2,057.23 +6.11 0.30%
NASDAQ 4,738.7810 +13.1420 0.28%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs